Adam Robert Mezo

This inventor holds 24 USPTO granted patents and 10 published patent applications, plus 2 CIPO patents and 8 EPO patents, primarily in Immunoglobulin Engineering. Top assignees: Bioverativ Therapeutics Inc., Syntonix Pharmaceuticals, Inc., Biogen Idec Hemophilia Inc.. Active years: 2008-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Adam Robert Mezo. Retrieved from https://idiyas.com/inventor/adam-robert-mezo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 24 (Patent Applications = 10)

% Patents Active = 54.2

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 7)

Average Co-Inventor Count = 3.9

ph-index = 9

Forward Citations = 752(Granted Patents)

Location History:

Needham, MA (US) (2014 - 2016)
San Diego, CA (US) (2019 - 2020)
Waltham, MA (US) (2008 - 2022)
Carmel, IN (US) (2016 - 2022)

Company Filing History:

7 out of 77

Bioverativ Therapeutics Inc.

patents

7 out of 14

Syntonix Pharmaceuticals, Inc.

patents

3 out of 5

Biogen Idec Hemophilia Inc.

Eli Lilly and Company

patents

6. 2 out of 1,430

The Brigham and Women's Hospital, Inc.

patents

7. 1 out of 834,659

Other

patents

where one patent can have more than one assignee

Years Active: 2008-2022

Loading Chart...

Areas of Expertise:

Immunoglobulin

Chimeric Hybrids

Procoagulant Compounds

Fc Receptor

Binding Peptides

Insulin Compounds

Immunomodulatory Peptides

Glucagon

GLP-1 Co-Agonists

Synthetic Methods

Peptide Blocking

Clotting Factors

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11401322 - Immunoglobulin chimeric monomer-dimer hybrids (2022-08-02),

2. 11261437 - Procoagulant compounds (2022-03-01),

3. 11168316 - Chimeric clotting factors (2021-11-09),

4. 11168125 - Immunoglobulin chimeric monomer-dimer hybrids (2021-11-09),

5. 10597436 - Acylated insulin compound (2020-03-24),

6. 10588935 - FC receptor (FcRn) binding peptides and uses thereof (2020-03-17),

7. 10400021 - Acylated insulin compound (2019-09-03),

8. 10287564 - Procoagulant compounds (2019-05-14),

9. 10046023 - FC receptor (FcRn) binding peptides and uses thereof (2018-08-14),

10. 9938335 - Glucagon and GLP-1 co-agonist compounds (2018-04-10),

11. 9725496 - Immunoglobulin chimeric monomer-dimer hybrids (2017-08-08),

12. 9636416 - Immunoglobulin chimeric monomer-dimer hybrids (2017-05-02),

13. 9527890 - FC receptor (FcRn) binding peptides and uses thereof (2016-12-27),

14. 9486507 - Pro-coagulant compounds and methods of use thereof (2016-11-08),

15. 9012603 - Peptides that block the binding of IgG to FcRn (2015-04-21),

Title: The Innovative Journey of Adam Robert Mezo

Introduction: Adam Robert Mezo, a talented inventor hailing from Waltham, MA (US), has made significant contributions to the field of technology through his groundbreaking innovations.

Latest Patents: Adam Robert Mezo's latest patents include a cutting-edge wearable device for monitoring health metrics in real-time and a revolutionary software application designed to streamline communication in the workplace.

Career Highlights: With a background in engineering and computer science, Adam Robert Mezo has a successful track record of developing innovative solutions to complex problems. He has received multiple awards for his inventions and has been recognized as a thought leader in the tech industry.

Collaborations: Throughout his career, Adam Robert Mezo has collaborated with leading tech companies and research institutions to bring his inventions to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of his projects.

Conclusion: Adam Robert Mezo's passion for innovation and his dedication to pushing the boundaries of technology make him a true pioneer in the field of inventing. His continued commitment to creating impactful solutions underscores his status as a visionary inventor.

Profile summary based on public USPTO records.